Dr. Safa Qays Albustani, MD

Dr. Albustani practices at Jersey Shore University Medical Center in Neptune, New Jersey, part of Hackensack Meridian Health.

Dr. Albustani's NPI, 1285195313, was assigned on March 29, 2019. Dr. Albustani holds New Jersey license 25MA11399600.

Dr. Albustani's primary practice is Jersey Shore University Medical Center, at 1945 Rte 33, Neptune, NJ 07754 in Monmouth County. The practice phone is (732) 775-5500.

Dr. Albustani's primary practice is Jersey Shore University Medical Center in Neptune, New Jersey, part of Hackensack Meridian Health. Dr. Albustani is also affiliated with JFK University Medical Center. The medical group on file is Plover Inpatient Services LLC. Dmand AI also links Dr. Albustani to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Albustani practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Albustani's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Albustani is licensed in New Jersey.

CMS data shows 1,530 Medicare services from Dr. Albustani across 6 procedure codes in 2024, for 602 Medicare patients. Medicare paid $145,201 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 602 Medicare patients who saw Dr. Albustani in 2024. The largest group is 75 to 84, with 216 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Albustani's median patient age at 73, with 44% women.

In 2024, Dr. Albustani wrote 298 Medicare Part D claims for 123 patients. 84% of them were for generic drugs. CMS names the drug for 49 of them, across 4 drugs with 11 or more claims each, at $265 in total drug cost. In 2023, CMS named 112 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 70 out of 100 for Dr. Albustani for performance year 2024, reported individually. Dr. Albustani accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Albustani, published from 2020 to 2022. 2021 was the busiest year, with 2. Dr. Albustani has published most often in Cureus. Dr. Albustani's most frequent co-authors are Ndausung Effiong Udongwo, MD, Saira Chaughtai and Eric Costanzo, DO.

CMS Open Payments shows 6 general payments to Dr. Albustani from 3 drug and device companies from 2020 to 2023. Food and beverage make up the largest share, 100% of the total. Abbott Laboratories paid the most, $41.